Introduction
In populations wherein replacement feeding is unfeasible, it has been estimated that between 25 and 35% of children born to HIV-infected pregnant women will become HIV infected [1] . Of these mother-to-child transmission (MTCT) events, estimates suggest that in a breast-fed population, 25-35% of MTCT occurs in utero prior to delivery, 40-55% during labor and delivery and the remaining 25-35% during breastfeeding [1] . Numerous studies have established that high maternal HIV-1 load is a major risk factor for HIV-1 MTCT [2] [3] [4] [5] [6] , and reduction of maternal HIV-1 RNA load with antiretroviral drugs significantly reduces the rate of HIV-1 MTCT [7, 8] . Additional factors such as chorioamnionitis [9] , syphilis [6] and possibly placental inflammation [9] [10] [11] have also been associated with HIV-1 MTCT. Although the timing of HIV-transmission is fairly clearly understood, apart from the aforementioned conditions, the molecular mechanism of HIV-1 MTCT is not well understood.
Previous studies from our group indicated that the HIV-1 RNA concentration in placental blood differs by HIV-1 vertical transmission status and that HIV-1 replicates locally in the placental environment [12] ; in the same study, we also observed phylogenetic evidence of HIV-1 compartmentalization in placentas isolated from women who transmitted HIV-1 in utero. Viral compartmentalization in the placenta suggests that HIV-1 can adapt to the placental microenvironment. One of the key components that may regulate HIV-1 replication in the placenta is the localized immune state. The maternal-placental interface is a unique immune environment characterized by a strong infiltrate of cells including natural killer cells, macrophages and dendritic cells [13] . These immune cells as well as resident placental cells such as trophoblasts are known to secrete a variety of cytokines, chemokines and growth factors [14] . The influences of these factors on both HIV-1 replication in vivo and HIV-1 MTCT are not fully understood.
Studies on sexual transmission indicate that innate immune defenses play a crucial role in transmission of simian immunodeficiency virus and HIV-1 by compromising the integrity of the vaginal mucosal barrier due to associated inflammation and by increasing target cell availability [15] . A microenvironment facilitating transmission may be created by chemokines [macrophage inflammatory protein (MIP) class] and pro-inflammatory cytokines [granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL) 1, IL-6 and IL-8) that recruit neutrophils, dendritic cells, macrophages and lymphocytes [16, 17] . Cytokines also play an important role in the early stages of viral infection by exhibiting direct antiviral activity, activating and recruiting various immune effector cells and modulating adaptive antiviral immune responses [18, 19] . Some cytokines and chemokines can upregulate HIV-1 expression in target cells, regulate the availability and activity of transcription factors that bind to the promoter of HIV-1 provirus, enhance expression of target cell receptors and recruit and activate resting CD4 þ T lymphocytes [20] [21] [22] [23] [24] [25] .
Although several groups have addressed the effect of specific cytokine responses in acute HIV-1 infection during sexual transmission [21, 26, 27] , only limited studies have addressed how placental innate immunity may modulate HIV-1 MTCT [28, 29] . We designed an exploratory study to interrogate cytokine, chemokine and growth factor levels in placental plasma isolated from 84 HIV-1 nontransmitting, 35 in-utero and 34 intrapartum transmitting mothers. The overall objective of this study is to determine whether immune modulation in the placental milieu is associated with HIV-1 MTCT. [6, 30] . Women were ineligible for MHP if they were in the active phase of labor, were participating in other research studies, were less than 15 years of age, had hypertension, multiple gestations or altered consciousness. Maternal HIV-1 status was determined by two rapid tests, as described previously [30] . Pregnant women with acute HIV infection [31] were excluded from this study. Women who delivered stillbirths or died at delivery were also excluded from the study. At the onset of active labor, women received a single dose of nevirapine and shortly after birth, infants received a single dose of nevirapine, both according to the HIVNET 012 protocol [8] . Infant HIV-1 status was determined by real-time PCR testing according to the methods of Luo et al. [32] , and pediatric HIV infection was categorized according to standard definitions [33] , as follows: HIV-1 transmission cases were classified as in-utero transmissions if infants were HIV-1 DNA positive within 48 h of birth, as intrapartum transmissions if infants were HIV-1 DNA negative at birth and HIV-1 DNA positive 6 weeks postpartum and as HIV-1 negative, or nontransmitters, if infant samples from both birth and 6 weeks postpartum were HIV-1 DNA negative. Overall, 1157 (30%) of the pregnant women in MHP were HIV-1 infected, with 73 (9%) of their newborns HIV-1 infected in utero and 66 (13%) infected intrapartum [6] . Maternal hemoglobin concentration was determined by Hemocue hemoglobinometer (HemoCue AB, Ä ngelholm, Sweden); CD4 þ T cells were quantified by FACScan (Becton Dickinson, San Jose, California, USA); HIV-1 RNA was quantified from peripheral and placental plasma using Amplicor HIV-1 Monitor v1.5 (Roche Diagnostics, Branchburg, New Jersey, USA), with plasma HIV-1 RNA concentrations less than 400 assigned a value of 400 copies/ml. Peripheral malaria was diagnosed using Geimsa-stained thick and thin blood smears and placental malaria was diagnosed based on placental histology, both as described in Mwapasa et al. [30] . Syphilis was diagnosed using the rapid plasma reagin test (RPR; Omega Diagnostics, Alloa, Scotland), and all RPR reactive sera were tested with the Treponema pallidum hemagglutination assay (TPHA; Omega Diagnostics). Participants with a reactive RPR followed by a reactive TPHA were considered syphilis seroreactive, as described [34] .
Patients and methods

Study participants and clinical isolates
Study design
Placental plasma was available from 35 women whose infants became HIV-infected in utero and 34 women whose infants became infected intrapartum. Owing to the exploratory nature of the study, the number of nontransmitter samples in the control group was selected based on the number of assays available per 96-well plate (n ¼ 84). The 84 nontransmitter samples were randomly chosen, using STATA (version 10.1; StataCorp., College Station, Texas, USA), from the total collection of nontransmitter samples with placental plasma available. By design, nontransmitter samples were not matched with either in-utero or intrapartum samples. The participants included in this study were similar to those not included with regard to maternal age, CD4 þ T-cell count and peripheral HIV-1 concentration (Wilcoxon rank-sum test, all P values greater than 0.3). When stratified by HIV-transmission status (nontransmitter, in utero, intrapartum), included and excluded participants were also similar, with the exception of peripheral viral load in the in-utero subgroup: the included in-utero samples had a lower peripheral viral load than those not included (4.7 vs. 5.1 log 10 copies/ml, Wilcoxon rank sum test, P ¼ 0.08).
Collection of placental plasma
After delivery of the placenta, an incision was made in the middle of the maternal surface of the placenta, 2-cm long and through half the thickness of the placental tissue. The placental blood that pooled in the incision was collected, and plasma was prepared according to standard protocols.
Luminex cytokine assay
Twenty-seven analytes were simultaneously quantified from 20 ml of placental plasma with a Bio-Plex Pro Human Cytokine 27-plex kit (BioRad, Hercules, California, USA) according to the manufacturer's instructions. The analytes include the following: IL-1b, IL-1Ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12(p70), IL-13, IL-15, IL-17, eotaxin, fibroblast growth factor (FGF) basic, granulocyte colonystimulating factor (G-CSF), GM-CSF, interferon (IFN)-g, interferon gamma-induced protein (IP) 10, monocyte chemoattractant protein 1, MIP-1a, MIP-1b, platelet-derived growth factor (PDGF)-BB, RANTES (Regulated upon Activation, Normal T-cell Expressed, and Secreted), tumor necrosis factor a and vascular endothelial growth factor (VEGF). Data were acquired using a Bio-Plex-200 suspension array system and the cytokine/chemokine concentrations were automatically calculated with Bio-Plex Manager software 5.0 using a standard curve derived from a recombinant cytokine standard (supplied by the manufacturer). When a limited number of the data were outside of the range of the standard curve, the values were set to the maximum or minimum value of the standard curve. The majority of the FGF basic, MIP-1a, VEGF and RANTES data were outside of the range of the standard curve and, therefore, were excluded from further analysis.
Evaluation of placental biopsies
A subset of the participants had representative formalinfixed, paraffin-embedded full-thickness placental biopsies available. Routine tissue sections were cut from placental biopsies and stained with hematoxylin and eosin (H&E), according to standard protocols. Histopathological analysis of placental sections was performed by an expert placental pathologist (N.C.R.). Light microscopy evaluation was performed using standard objectives (4Â, 10Â, 20Â and 40Â). The presence or absence of histological placental parenchymal abnormalities was noted, including edema, increased syncytial knots, changes in the villous vasculature, placental maturity and nonspecific acute and/or chronic villitis and/or intervillositis. Histological evidence of infection with the ToRCHES microbes (Toxoplasma, Rubella, Cytomegalovirus, Herpes, Enteroviruses, and Syphilis), which are known to cross the maternal-fetal barrier, was also assessed. Chorioamnionitis was assessed by a single pathologist (D.A.M.) according to methods previously described [35] . Briefly, H&E stained sections of cord, membranes and placenta and/or Giemsa-stained sections of placenta were evaluated under light microscopy for the presence of neutrophils in the chorion, amnion, umbilical cord and fetal plate. Both pathologists were masked to the HIV-1 transmission status of the participants.
Statistical analysis
Statistical analysis was performed with STATA and SAS (version 9.2, Cary, North Carolina, USA). The Wilcoxon rank-sum test or the Fisher's exact test was used to compare clinical and virological features between the transmission groups. Univariate associations were tested with a two-sample Wilcoxon rank-sum test, with in utero and intrapartum considered as separate outcomes. As this is an exploratory study, we did not correct for multiple hypothesis testing [36] , except as a sensitivity analysis of our main findings. In that case, we applied a Bonferroni correction (P value cutoff ¼ 0.05 divided by 23 analytes equals an adjusted P value cutoff of 0.002). To further explore the association between IP-10 and in-utero MTCT, we used regression models specifying the Poisson distribution, with IP-10 as the primary exposure and transmission status (in utero vs. nontransmitters) as the outcome; intrapartum transmission events were excluded from the multivariable modeling analyses. All cytokine measures were log 10 transformed prior to modeling. The exposure variable and all covariates met the assumption of linearity in the log risk. On the basis of previous literature and preliminary analysis, we assessed maternal age, gestational age, CD4 þ T-cell count, hemoglobin level, maternal temperature at delivery, IL-4, IL-5, IL-6, IL-7, IL-9, eotaxin and IL-1Ra as potential confounders. The full model was reduced using manual backward elimination [37] . We assessed potential confounders one by one and retained those variables that changed the main effect estimate by more than 10% when removed from the full model.
Results
Participant characteristics
We designed a case-control study to compare the concentration, in placental blood, of several chemokines, cytokines and growth factors stratified by HIV-1 MTCT status. In total, 153 placental plasma isolates were included in the analysis: 35 from cases of in-utero transmission (in-utero MTCT), 34 from cases of intrapartum transmission (intrapartum MTCT) and 84 from cases of HIV-exposed but uninfected (nontransmitters). The three groups were balanced for most maternal characteristics, with the exception of gestational age (slightly lower among cases of in-utero MTCT) and both peripheral and placental viral load (higher among both in-utero and intrapartum MTCT cases) ( Table 1) .
Multiple cytokines and chemokines are associated with in-utero HIV-1 mother-to-child transmission The primary objective of this study was to compare analyte levels in placental blood isolated from motherinfant pairs with known HIV-transmission status ( Table 2) . Median analyte levels in each of the transmission categories were consistent with previously published range of analyte concentrations [27] . Owing to the likelihood that in-utero and intrapartum MTCT occur via different biological mechanisms, we analyzed the data as two separate casecontrol studies, nontransmitters vs. in utero and nontransmitters vs. intrapartum. Eight analytes in placental blood were significantly higher in cases of in-utero transmission compared with nontransmitters ( Table 2 and Fig. 1 ): IL-4 (36%), IL-5 (200%), IL-6 (56%), IL-7 (35%), IL-9 (218%), eotaxin (162%), IL-1Ra (190%) and IP-10 (252%). In contrast, only G-CSF was elevated during intrapartum MTCT, by 159%. After correcting for multiple comparisons, only the association between IP-10 and in-utero MTCT remained statistically significant. These data suggest that the placental environment, specifically the cytokines and chemokines present in the placenta, differs by both HIV-1 transmission status and by mode of transmission.
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AIDS 2012, Vol 26 No 6 G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; IL, interleukin; IP, intrapartum transmission; IP-10, interferon gamma-induced protein 10; IQR, interquartile range; IU, in-utero transmission; MCP1, monocyte chemoattractant protein 1; MIP, macrophage inflammatory protein 1; MTCT, mother-to-child transmission; NT, nontransmitter; PDGF-B, plateletderived growth factor B; TNF-a, tumor necrosis factor a. Analyte values in the transmission groups were compared using a Wilcoxon rank-sum test.
NT IU  IP  NT  IU  IP  NT  IU  IP   NT  IU  IP  NT  IU  IP  NT  IU  IP   NT  IU  IP  NT  IU  IP  NT  IU We examined a matrix of correlation coefficients to evaluate the association between CD4 þ T-cell count, HIV-1 RNA concentration and the chemokines and cytokines that were associated with in-utero MTCT ( Table 3) . Although several of the analytes were strongly correlated with each other, none was strongly or significantly associated with CD4 þ T-cell count. IP-10 was significantly yet weakly correlated with peripheral HIV-1 RNA level and strongly correlated with placental HIV-1 RNA level. Participants with placental malaria had higher levels of IP-10 in placental plasma than participants without evidence of placental malaria (2.4 vs. 2.7 log 10 pg/ml IP-10, P ¼ 0.05, Wilcoxon rank-sum test). Previous studies have documented an association between IP-10 levels in amniotic fluid and chorioamnionitis, but we observed no correlation between IP-10 concentration in placental plasma and chorioamnionitis (P ¼ 0.3, two-sample Wilcoxon rank-sum test).
Placental histology
In order to exclude microbial infection of the placenta, we analyzed placental biopsies for evidence of histological abnormalities. A total of 94 biopsies were available for analysis: 56 of 84 nontransmitters (67%), 17 of 35 in utero (49%) and 21 of 34 intrapartum (62%). This subset of placental biopsies was a convenience sample and did not differ from the parent population in regard to peripheral HIV-1 concentration, CD4 þ T-cell count, gestational age, maternal age, IL-4, IP-10 or IFN-g levels (data not shown). We observed no significant microscopic placental pathological findings associated with in-utero MTCT, including those traditionally associated with malaria or ToRCHES infections. However, edema, either in the placenta or in the fetal membranes, was observed in 10 nontransmitters (20%), six in-utero (38%) and 10 intrapartum (50%) biopsies (nontransmitters vs. in utero, P ¼ 0.2; nontransmitters vs. intrapartum, P ¼ 0.02; Fisher's exact test). We identified several curious findings, including a less-than-typical amount of fibrin in the intervillous space and a high prevalence of syncytial knots, although neither feature was associated with HIV-1 transmission (data not shown).
Regression analysis
Our preliminary analyses suggested that IP-10 may be meaningfully associated with in-utero MTCT. In a univariate Poisson regression analysis, every log 10 increase in IP-10 increased the prevalence of in-utero MTCT by 70% [prevalence ratio: 1.7, 95% confidence interval (CI): 1.3-2.3]. We built a multivariate Poisson regression model with in-utero MTCT as the dependent variable, IP-10 as the primary exposure variable of interest and all covariates found to be significant in univariate analyses as potentially confounding variables. After backward elimination, gestational age, IL-4, IL-5, IL-7 and IL-1Ra were retained as confounders (Table 4 ). Maternal age and CD4 þ T-cell count were kept in the final regression model for a priori considerations even though they did not meet the 10% criterion for confounding. The remaining variables (temperature, hemoglobin, IL-6, IL-9 and eotaxin) were not retained. After adjustment, every log 10 increase in IP-10 increased the prevalence of inutero MTCT more than three-fold (prevalence ratio: 3.3, 95% CI: 1.3-8.1). We conducted two sensitivity analyses: one including placental viral load in place of CD4 þ T-cell count in the final model and the other including peripheral viral load in place of CD4 þ T-cell count in the final model (models containing CD4 þ T-cell count together with either viral load variable did not converge due to collinearity.) Both viral load variables had considerable missing data, leading to a loss of 37 and 12% of patients, respectively, when placental or peripheral viral load were used in place of CD4 þ T-cell count. For the model containing placental viral load, the prevalence ratio for IP-10 was similar to the primary analysis (prevalence ratio: 3.6, 95% CI: 1.0-13). For the model containing peripheral viral load, the prevalence ratio for in-utero MTCT was again similar at 3.7 (95% CI: 1.2-11). Both sensitivity analyses indicated that use of CD4 þ T-cell count instead of viral load did not meaningfully change the magnitude of the observed effect of IP-10 on 690 AIDS 2012, Vol 26 No 6 in-utero MTCT, though precision of the estimate after adjustment for viral load suffered because of missing data leading to smaller sample size.
Discussion
The objective of this exploratory case-control study was to determine whether the levels of chemokines, cytokines or growth factors in placental plasma were associated with HIV-1 MTCT. We observed the following: IL-4, IL-5, IL-6, IL-7, IL-9, eotaxin, IL-1Ra and IP-10 levels and HIV-1 RNA concentration were higher in placental plasma from in-utero MTCT than in placental plasma from nontransmitter controls, only G-CSF was elevated in placental plasma prepared from intrapartum MTCT cases compared with placental plasma from nontransmitter controls and after adjustment for confounding variables and either CD4 þ T-cell number or viral load, multivariate modeling indicated that IP-10 levels were independently associated with a three-fold increase in the prevalence of in-utero MTCT. These observations suggest that an altered immune environment in the placenta is associated with in-utero MTCT and not intrapartum MTCT.
Many of the analytes elevated in placental plasma during in-utero MTCT have previously been associated with HIV-1 infection. For example, IL-1Ra, an inducible receptor antagonist of IL-1, is known to be elevated in inflammatory diseases, including HIV-1, in which it may serve as a marker of disease progression [38] [39] [40] [41] . Increased levels of IL-7 is consistent with other studies; however, these studies also found increased IL-7 in correlation with the level of CD4 þ T-cell depletion, suggesting the role of IL-7 in T-cell apoptosis and hence disease progression [42] [43] [44] . However, a similar association between IL-7 and CD4 þ T-cell count was not observed in these samples (Table 3) . IL-6 is considered a pro-inflammatory mediator and has been shown to induce HIV-1 replication by both transcriptional and posttranscriptional mechanisms [45] . On the contrary, HIV-1 infection is also known to induce IL-6 [46, 47] , which confounds our ability to interpret the association between in-utero MTCT, IL-6 and HIV-1 RNA concentration in placental blood. IL-4 is an important regulator and marker of accelerated HIV-1 disease progression and has been shown to collaborate with HIV-1 to induce IL-6 production, thereby resulting in global B-cell dysfunction [48, 49] . Finally, IL-5 and eotaxin can both recruit eosinophils, which have been shown to be permissive targets for HIV-1 replication [50, 51] .
The observed changes in multiple placental cytokine/ chemokine profiles during in-utero MTCT is in stark contrast to the placental cytokine/chemokine profile during intrapartum MTCT, in which only G-CSF level was elevated. The observed contrast in cytokine levels between in-utero and intrapartum MTCT provides additional data to support the hypothesis that in-utero and intrapartum MTCT have different molecular mechanisms. Consistent with this hypothesis, we (and others) have previously observed no association between maternal-fetal blood admixture (also called placental microtransfusions) and in-utero MTCT [52] [53] [54] ; in contrast, using two different assays, we have observed an association between placental microtransfusions and intrapartum MTCT [52, 53] . Whether or not the prevalent edema that was associated with intrapartum MTCT is related to placental microtransfusions cannot be determined from this study.
IP-10, also called CXCL10, is a type 1 chemokine that binds to the CXCR3 receptor [55] and attracts Th1 lymphocytes, monocytes, eosinophils and dendritic cells, many of which are permissive to HIV-1 infection and replication. In this study, IP-10 was significantly correlated with peripheral and placental HIV-1 RNA concentration, and IP-10 levels were independently correlated with in-utero MTCT. IP-10 has been shown to increase HIV-1 BAL replication in monocyte-derived macrophages and peripheral blood lymphocytes [56] , which could explain the elevated HIV-1 RNA concentration in placentas obtained from in-utero MTCT cases; to our knowledge, data demonstrating a direct affect of IP-10 on HIV-1 replication in the placental microenvironment has not been reported. Given the sequence variability within in the HIV-1 promoter [57] , further studies are needed to determine whether all HIV-1 variants replicate similarly when IP-10 signaling cascades are activated. Other studies have shown that IP-10 levels in peripheral blood are transiently induced during the acute stage of HIV-1 infection [27] and during untreated, progressive HIV-1 infection [58] . Malaria infection has been associated with both increased levels of IP-10 [59, 60] and leukocyte infiltration into the placenta [61, 62] , each of which could potentially create an environment favoring HIV-1 replication. In this study, we observed a small yet significant association between placental malaria and placental IP-10 levels; as we have previously reported in the parent MHP cohort, placental malaria was associated with an increased HIV-1 concentration in the placenta [30] , but it was not associated with an increased prevalence of HIV-1 MTCT [6] .
Multiple cell types secrete IP-10, including keratinocytes, endothelial cells, macrophages and fibroblasts in the adult [63] and Hofbauer cells, stromal cells and endothelial cells on the fetal side of the maternal-fetal interface [64] . Preterm infants can have transiently elevated IP-10 levels [65] . Although we interpret cytokine and chemokine levels in placental blood to reflect their concentration in maternal blood in the intervillous space, it is also possible that the method of blood collection used in this study (incision) created maternal-fetal blood admixture [66] .
Only by repeating the cytokine/chemokine arrays on umbilical cord blood could we conclusively determine whether the data reflect the cytokine storm in the fetus. Unfortunately, this type of specimen is not available from this study. Several observations from our previous study [12] , which used samples from the same cohort obtained using the same method of placental blood collection, argue against placental blood representing only fetal blood. First, we sequenced HIV-1 envelope genes from peripheral blood, placental blood and umbilical cord blood, and the collection of env genes in both maternal and placental blood were highly diverse, in stark contrast to the nearly homogenous viral population in cord blood. If the placental blood only represented fetal blood, we would expect it to have minimal viral sequence diversity. Second, phylogenetic reconstruction identified a fetal compartment of HIV-1 that was distinct from the placental compartment [12] . However, even if our findings reflect the cytokine/chemokine profile following acute fetal HIV-infection, they are consistent with a previous report of elevated plasma IP-10 in plasma donors acutely infected with HIV-1 [27] .
In summary, this study supports the association between elevated levels of specific cytokines and chemokines in placental plasma and in-utero, but not intrapartum, MTCT. IP-10 levels were independently associated with in-utero MTCT, and this association remained after controlling for maternal immune status and other confounding variables. These data may provide a direct link between the placental immunological state and viral replication, either through direct enhancement of HIV-1 transcription or via localized recruitment of cells that are permissive to HIV-replication.
